As of 2026-03-18, the EV/EBITDA ratio of Turning Point Therapeutics Inc (TPTX) is -10.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TPTX's latest enterprise value is 3,484.99 mil USD. TPTX's TTM EBITDA according to its financial statements is -340.81 mil USD. Dividing these 2 quantities gives us the above TPTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.9x - 24.1x | 12.2x |
| Forward P/E multiples | 15.1x - 24.2x | 16.8x |
| Fair Price | (97.78) - (159.67) | (93.49) |
| Upside | -228.6% - -310.1% | -223.0% |
| Date | EV/EBITDA |